Skyley pre-sale divestiture of affiliated pharmaceutical marketing company

On December 16, Tianshili will sell Tianshi Marketing, Tianshili announced that the Company and Chongqing Pharmaceutical (Group) Co., Ltd("Chongqing Pharmaceuticals") have signed a "Framework Agreement" and agreed to sell the shares of Tianjin Tianshi Li Pharmaceutical Marketing Group Co., Ltd("Tianshi Marketing"), a controlling subsidiary of the companythis Cypress blue the first time to the Tianshi Li aspect of understanding, Tianshi Li to Cypress Blue said that at this stage, it is not convenient to say more content, specifically to the public disclosure of informationaccording to the Framework Agreement, Chongqing Pharma intends to acquire 87.47 percent of the company's direct and indirect shares in Tianshi Marketing by paying cash consideration, as well as the shares held by other shareholders of Tianshi Marketingalso under the Framework Agreement, Chongqing Pharma will also purchase a 100 percent stake in Shaanxi Tianshili Pharmaceutical Logistics Co., Ltd., held by Tianshili HoldingsAccording to Cypress Blue inquiry, Tianshili's subsidiaries are: Tianjin Tianshili Pharmaceutical Marketing Group Co., Ltd., Tianjin Tianshili Pharmaceutical Sinful Pharmaceutical Commercial Co., Ltd., Tianjin Tianshili Modern Chinese Medicine Resources Co., Ltd., Shaanxi Tianshili Plant Pharmaceutical Co., Ltd., Jiangsu Tianshi Li DiYi Pharmaceutical Co., Ltd., Tianshili Biopharmaceutical Co., LtdTianshi Marketing, a year revenue of 11.6 billionpublic information shows that Tianshi Marketing is mainly responsible for The pharmaceutical business business sector, mainly engaged in pharmaceutical, medical equipment, health care products and other products distribution and distribution, retail chain and chronic disease management and pharmaceutical value-added servicesas a pharmaceutical circulation enterprise, Tianshi Marketing to the upstream pharmaceutical industry enterprises or pharmaceutical distribution companies to purchase drugs, medical equipment, etc, to downstream distributors, medical institutions at all levels, pharmacies and other end customers for distribution and distribution, through the purchase and sale difference to obtain profitsAccording to Tianshili's 2019 semi-annual report, Tianshi Marketing currently has the distribution and distribution of pharmaceuticals, medical devices and radiation in Shaanxi, Beijing, Liaoning, Tianjin, Shandong, Hunan, Guangdong, Shanxi eight provinces and citiesin addition, Tianshi Marketing also in Liaoning Province, Tianjin, Shandong Province, Guangdong Province and other regions to open chain drugstores, to self-employed pharmacies, to join pharmacies as a supplement, and with online pharmacies for medical e-commerce services, Sky marketing's total operating income for 2018 was RMB116,593.14 million, and net profit was RMB10,359.3 million, accounting for 64.81 percent and 6.30 percent of Tianshi's total operating income and net profit for 2018, respectivelyin addition, Shaanxi Tianshili Logistics is a pharmaceutical three-way logistics company, mainly for the pharmaceutical and health industry supply chain upstream and downstream to provide three-way logistics servicesTianshili will focus more on the pharmaceutical industry
Tianshili's 2019 half-year lying report shows that in the first half of 2019, its operating income increased 11.10% from a year earlier, of which the pharmaceutical industry revenue increased by 0.62%, pharmaceutical business revenue increased 17.89%, pharmaceutical commercial sector sales revenue of 6,070 million yuan, accounting for 64.72% of the company's main business income Tianshili said that the transfer of subsidiary equity is based on its strategic development needs, in order to further focus on the pharmaceutical industry business, enhance core competitiveness according to the announcement, if the transaction can be successfully completed, the company will no longer hold a stake in Tianshi Marketing through this asset sale, Tianshili will further focus on the pharmaceutical industry, continue to promote the coordinated development of modern Chinese medicine, biological medicine and chemical drugs, and build an innovative pharmaceutical research and development cluster 's acquisition of Heavy Drug Holdings, in order to expand the national market the same day, Heavy Drug Holdings also announced the matter According to Cypress Blue inquiry, Heavy Drug Holdings is the key backbone of the SASAC in Chongqing, mainly engaged in the wholesale and retail of pharmaceutical and medical devices public information shows that heavy drug holding business has covered 31 provinces (municipalities and autonomous regions), established 14 pharmaceutical commercial provincial platform, in the core sales area of Chongqing, has achieved the full coverage of tertiary A and other medical institutions, the basic coverage of secondary hospitals, Chongqing City, the second level or above (including the second level) medical institutions coverage of more than 80% variety operation, heavy drug holding selling a variety of pharmaceutical commodities more than 80,000, including prescription drugs, over-the-counter drugs, vaccines, narcotics, Chinese herbal medicine, health care products, medical equipment and other diverse varieties of combination, with more than 7,000 domestic and foreign suppliers to maintain cooperative relations, Chongqing and even the west of the preferred first-level distributors in the view of Heavy Drug Holdings, through this asset acquisition, Heavy Drug Holdings will effectively expand the sales area, accelerate the pace of national network layout, in order to achieve the "national" strategic objectives to lay a solid foundation at the same time, both sides said that through this transaction, will establish long-term good relations of cooperation in the field of pharmaceutical business, and ultimately achieve the strategic goal of win-win cooperation original title: Heavy! Well-known pharmaceutical companies spin off marketing companies